Ninth International Symposium on Regional Cancer Therapies

  • 903 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
903
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Nonprofit Org. U.S. Postage PAID Pittsburgh, PA Permit No. 3834 February 15 –17, 2014 Ninth International Symposium on Regional Cancer Therapies Sheraton Steamboat Springs Steamboat Springs, Colorado Course Co-Directors H. Richard Alexander, MD Sponsored by Regional Cancer Therapy Center and University of Pittsburgh School of Medicine https://ccehs.upmc.com For additional information or to register online, contact: Sheraton Steamboat Springs, Steamboat Springs, Colorado Regional Cancer Therapies Ninth International Symposium on February 15 –17, 2014 Pittsburgh, PA 15232 5150 Centre Avenue UPMC Cancer Pavilion, Suite 413 David C. Koch Regional Cancer Therapy Center David C. Koch Center for Continuing Education in the Health Sciences and UPMC Cancer Centers Professor of Surgery University of Maryland School of Medicine Baltimore, Maryland David L. Bartlett, MD Professor of Surgery University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania Robert P. Edwards, MD Professor, Obstetrics, Gynecology and Reproductive Sciences In Collaboration with The University of Maryland Marlene and Stewart Greenebaum Cancer Center The Medical College of Wisconsin Cancer Center University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania T. Clark Gamblin, MD, MS Associate Professor of Surgery Medical College of Wisconsin Milwaukee, Wisconsin
  • 2. Intent and Overview Schedule – Saturday, February 15, 2014 This course is designed to cover the most recent advances in cancer therapy that are primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian and thoracic. Upon completion of the activity, learners from several disciplines should be able to discuss the latest regional therapies in surgical oncology. This course is designed for physicians and nurses practicing in the areas of Medical, Surgical, Thoracic and Gynecologic Oncology and Gastroenterology. Continuing Education Credit The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this educational activity for a maximum of 19.0 AMA PRA Category 1 Credits™. Each physician should claim only credit commensurate with the extent of their participation in the activity. Other health care professionals are awarded 1.90 continuing education units (CEU’s) which are equal to 19.0 contact hours. Special Needs Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by calling Maureen Hewko at (412) 623-5993. The University of Pittsburgh, as an educational institution and as an employer, values equality of opportunity, human dignity, and racial/ethnic and cultural diversity. Accordingly, as fully explained in Policy 07-01-03, the University prohibits and will not engage in discrimination or harassment on the basis of race, color, religion, national origin, ancestry, sex, age, marital status, familial status, sexual orientation, gender identity and expression, genetic information, disability, or status as a veteran. The University also prohibits and will not engage in retaliation against any person who makes a claim of discrimination or harassment or who provides information in such an investigation. Further, the University will continue to take affirmative steps to support and advance these values consistent with the University’s mission. This policy applies to admissions, employment, and access to and treatment in University programs and activities. This is a commitment made by the University and is in accordance with federal, state, and/ or local laws and regulations. For information on University equal opportunity and affirmative action programs, please contact: University of Pittsburgh; Office of Affirmative Action, Diversity, and Inclusion; Carol W. Mohamed, Director (and Title IX, 504 and ADA Coordinator); 412 Bellefield Hall; 315 South Bellefield Avenue; Pittsburgh, PA 15260; 412-648-7860. For complete details on the University’s Nondiscrimination Policy, please refer to Policy 07-01-03. For information on how to file a complaint under this policy, please refer to Procedure 07-01-03. ~2~ Registration and Breakfast 7:00 am Welcome Who Should Attend 6:45 am Moderators: Steven Ahrendt, MD and James Cusack, MD 7:15 am Peritoneal Surface Disease with Synchronous Hepatic Involvement Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Andrea Doud, MD, et. al. 7:30 am 7:45 am 8:00 am 8:15 am Nomograms to Predict Prognosis in Pseudomyxoma Peritonei: A PSOGI Multicenter Study Shigeki Kusamura, MD, et. al. Extra-appendiceal Origin does not Affect Prognosis in Patients with Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and HIPEC Dario Baratti, MD, et. al. Evaluation of a New Staging Classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 210 Patients with Mucinous Appendiceal Neoplasms Jesus Esquivel, MD, et. al. GUEST LECTURER Comprehensive Palliative Care for Peritoneal Carcinomatosis Laura Lambert, MD 8:45 am Break with Refreshments/Exhibitors Moderators: Fabian Johnston, MD and Amer Zureikat, MD 9:00 am Learning Curve and Outcomes of Cytoreductive Surgery and HIPEC for Peritoneal Malignancies Patricio Polanco, MD, et. al. 9:15 am HIPEC in Peritoneal Dominant Metastatic Colorectal Cancer Robert Martin, MD, et. al. ~3~
  • 3. 9:30 am 9:45 am What is the Impact of Diaphragmatic Involvement During Cytoreductive Surgery/HIPEC on Short Term Outcomes? Bernardo Franssen, MD, et. al. 6:00 pm GUEST LECTURER Is there a Role for HIPEC in Ovarian Cancer? C. William Helm, MB.BChir 6:30 pm Light Dinner/Exhibitors DEBATE HIPEC for Colorectal Cancer — Investigational vs. Standard of Care Garrett Nash, MD and Jesus Esquivel, MD Moderators: Douglas Tyler, MD and Charlotte Ariyan, MD 10:15 am Break Until Evening Session 6:45 pm 4:00 pm Poster Viewing and Grading Establishment of a National Guideline for the Use of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Surface Malignancies in Austria Thomas Bachleitner-Hofman, MD, et. al. Moderators: Marilyn Huang, MD and Marcello Deraco, MD 4:30 pm Comparison of MRI and CT for Predicting the Peritoneal Cancer Index (PCI) Preoperatively in Patients Being Considered for Cytoreductive Surgical Procedures Russell Low, MD, et. al. 4:45 pm Association Between Hospital Finances, Payer Mix, and Complications After HIPEC: Deficiencies in the Current Healthcare Reimbursement System and Future Implications Charles Staley, MD, et. al. 5:00 pm Maximal Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Paolo Sammartino, MD, et. al. 7:00 pm Accordion Severity Grading and Aggregate Postoperative Morbidity Burden of CS-HIPEC in a Community Hospital Jan Franko, MD, et. al. Quality of Life After Isolated Limb Infusion for In-transit Melanoma of the Extremity Betty Jiang, MD, et. al. 7:30 pm Hyperthermic Isolated Limb Perfusion (ILP) with Curaxins for Melanoma Minhyung Kim, MD, et. al. 7:15 pm 7:45 pm Isolated Limb Infusion is Feasible at Lower Volume Regional Cancer Centers David Jeffcoach, MD, et. al. 5:15 pm Intraperitoneal Chemotherapy and Ileostomies in Ovarian Cancer Gleneara Bates, MD, et. al. 5:30 pm Obesity, Lymphadenectomy, and Survival Outcomes in Intermediate to High-risk, Early Stage Endometrial Cancer Patients Faina Linkov, MD, et. al. DEBATE First Line Treatment for in Transit Melanoma — Systemic vs. Regional Steven O’Day, MD and John Kane III, MD 8:30 pm Evening Session Adjournment Cytoreductive Surgery (CRS) and HIPEC in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma C. Komen Brown, MD, et. al. 8:45 pm Meet the Speakers Reception 5:45 pm ~4~ 8:00 pm ~5~
  • 4. 9:15 am 6:45 am Post-TACE Neutrophil-to-Lymphocyte Ratio is Predictive of Survival in Patients with Unresectable Neuroendocrine Liver Metastases Neil Saunders, MD, et. al. Registration and Breakfast 7:00 am Radioembolization for Unresectable Colorectal Liver Metastases Anthony Zacharias, MD, et. al. 9:30 am Sunday, February 16, 2014 Welcome Moderators: T. Clark Gamblin, MD, MS and Martin Goodman, MD Neutrophil-lymphocyte Ratio: A Simple and Novel Biomarker for Prediction of Survival After Radioembolization for Metastatic Colorectal Cancer Samer Tohme, MD, et. al. 7:30 am Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors: A Single Institution Review of 197 Patients Lawrence Shirley, MD, et. al. 7:45 am Hepatic Artery Infusion for Recurrent or Chemoresistant Hepatic Malignancy Harold Wanebo, MD, et. al. 7:15 am 8:00 am Quality of Life Improvement and Enhanced Efficacy with Hepatic Arterial Therapy of Doxorubicin-loaded beads (DEBDOX) in the Treatment of Liver Metastases from Ocular Melanoma Robert Martin, MD, et. al. 8:15 am GUEST LECTURER Radioembolization and Chemoembolization 2014: Current Status and Future Trends William Rilling, MD 8:45 am Break with Refreshments/Exhibitors Results and Feasibility of Sequential Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion (PHP) With Melphalan for Patients with Liver Metastases Mei Li Kwong, MD, et. al. DEBATE High Grade, High PCI Carcinomatosis: Is There a Role for CRS and HIPEC? John Stewart, MD (Yes) and Kiran Turaga, MD (No) 10:15 am Break Until Evening Session 4:00 pm Poster Viewing and Grading Moderators: C. Komen Brown, MD and Daniel Labow, MD 4:30 pm Outcomes Following Cytoreductive Surgery and HIPEC in 44 Patients with Peritoneal Mesothelioma Oliver Shihab, MD, et. al. 4:45 pm Iterative Cytoreductive Surgery and HIPEC for Recurrent Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome Chukwuemeka Ihemelandu, MD, et. al. Cytoreductive Surgery with HIPEC for Signet Ring Peritoneal Malignancies Sarah McPartland, MD, et. al. 5:15 pm Cytoreductive Surgery and HIPEC in Children and Adolescents: the First 50 Cases Andrea Hayes-Jordan, MD, et. al. 5:30 pm Peritoneal Dominant Metastatic Colorectal Cancer Robert Martin, MD, et. al. 5:45 pm Conversion Gastrectomy after Intravenous Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites Joji Kitayama, MD, et. al. 5:00 pm Moderators: James Pingpank Jr., MD and Joel Baumgartner, MD 9:00 am 9:45 am ~6~ ~7~
  • 5. 6:00 pm Monday, February 17, 2014 GUEST LECTURER Pathologic Classification of PMP — Results of Basingstoke Consensus Conference Norman Carr, MD 6:30 pm Light Dinner/Exhibitors 7:00 am Moderators: Nathan Bahary, MD, PhD and Richard Royal, MD 6:45 pm Neoadjuvant Laparoscopic HIPEC for Peritoneal Metastases from Gastric Cancer Yutaka Yonemura, MD, et. al. 7:00 pm Cytoreductive Surgery with HIPEC — an Emerging Treatment Option for Advanced Goblet Cell Tumors of the Appendix Yarrow McConnell, MD, et. al. 6:45 am Registration and Breakfast Moderators: Jason Foster, MD and Timothy Kennedy, MD Impact of Distal Pancreatectomy on Outcomes of Peritoneal Surface Disease Treated with Cytoreductive Surgery and HIPEC Andrea Doud, MD, et. al. 7:15 am 7:30 am 7:45 am 7:15 pm Heated Intraperitoneal Gemcitabine for Resectable Pancreatic Carcinoma: Morbidity and Early Survival Data from Two Centers Lana Bijelic, MD, et. al. Management of Peritoneal Carcinomatosis in Columbia: Developing a National Center for Excellence Fernando Arias, MD, et. al. 7:45 pm Intraperitoneal Chemotherapy is Not Associated with Increased 30-Day Operative Morbidity and Mortality: A Matched Study of Colorectal Cancer Patients with and without Intraperitoneal Chemotherapy Edmund Bartlett, MD, et. al. 7:30 pm 8:00 pm GUEST LECTURER Video Demonstration of Five Parietal Peritonectomy Procedures Used for Cytoreductive Surgery of Peritoneal Metastases Paul Sugarbaker, MD, FACS, FRCS 8:00 am 9:30 pm American Society of Peritoneal Surface Malignancies Fourth Annual Meeting Evening Session Adjournment ~8~ Role of Obesity in the Proliferation and Metastasis of Endometrial and Ovarian Adenocarcinoma Faina Linkov, MD, et. al. Immunohistochemical Evaluation of Calretinin, Claudin, WT-1, Podoplanin, CK 5/6, Topoisomerase IIa, MCM7, ER, and PGR in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray Marcello Deraco, MD, et. al. GUEST LECTURER Pre-Clinical Research for Appendiceal Cancer: Where We’ve Been and Where We Need to Go Haroon Choudry, MD 8:45 am Break and Exhibitors Moderators: Brian Loggie, MD and Herbert Zeh III, MD 9:00 am Histologic Changes Associated with HIPEC Patrick Wagner, MD, et. al. 9:15 am Next Generation Sequencing Reveals Significant Genomic Heterogeneity in Appendiceal Neoplasms Laura Lambert, MD, et. al. 8:30 pm Morbidity of Abdominal Wall Resections (AWR) and Reconstructions During Cytoreductive Surgery and HIPEC Maria Nunez, MD, et. al. 9:30 am Oncolytic Vaccinia Virus and Irinotecan Synergize to Improve Treatment of Colorectal Carcinomatosis J. Andrea McCart, MD, et. al. ~9~
  • 6. A New Micronutrient Formulation with Hyperthermic Mitomycin C Enhances Colorectal Tumor Cell Killing in Vitro Daniel Cucher, MD, et. al. Poster Presentations 1. Hospital Factors that Contribute to Inpatient Mortality in Patients with Peritoneal Carcinomatosis: Larger Hospitals are Not Better. Evan Glazer, MD, et. al. 2. The Effects of Hyperthermia on Cytotoxicity of Intracavitary Chemotherapeutic Drugs Gleneara Bates, MD, et. al. Old Versus Too Old for Surgery in Patients with Peritoneal Carcinomatosis. Evan Glazer, MD, et. al. 3. 10:15 am Case Presentations/Panel Discussion Neoadjuvant Pelvic Perfusion May Facilitate Resection of Pelvic Recurrent Rectal Cancer. Harold Wanebo, MD, et. al. Case Discussants: H. Richard Alexander, MD, and Edgar Guillermo Flores-Ayala, MD 9:45 am 10:00 am Cardiac Toxicity Associated with Intraperitoneal Administration of Mitomycin C Sarah McPartland, MD, et. al. Cytoreductive Surgery (CRS) and HIPEC in a Patient with Previous Kidney/Pancreas Transplant Charles Staley, MD, et. al. Rare Presentation of Primary Papillary Serous Carcinoma (PSCP) in a Male Patient Charles Staley, MD, et. al. Cytoreductive Surgery and HIPEC for Desmoplastic Small Round Cell Tumor Jason Denbo, MD, et. al. Combined Systemic and Regional Therapy in a Young Adult with Peritoneal Carcinomatosis from Small Bowel Adenocarcinoma Teresa Kim, MD, et. al. Use of a Treatment Efficacy Score in Predicting Patients at Risk for Extensive Early Recurrence after CRS and HIPEC for Peritoneal Carcinomatosis Arising from the Appendix Nelson Royall, MD, et. al. 11:45 am Announcement and Poster Presentation of Poster Award Winners 11:50 am Conference Adjournment 4. Escalation of Socioeconomic Disparities Among Patients with Colorectal Cancer Receiving Advanced Surgical Treatment. Parissa Tabrizian, MD, et. al. 5. Laparoscopic Evacuation of Mucinous Ascites for Palliation in Unresectable Pseudomyxoma Peritonei. Kaitlyn Kelly, MD, et. al. 6. Pancreatic Fistulae in Patients Undergoing Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Distal Pancreatectomy are more Severe than those Undergoing Distal Pancreatectomy Alone. Stephanie Downs-Canner, MD, et. al. 7. Predictors of Progression in Patients with High-Grade Appendiceal or Colorectal Adenocarcinoma After Cytoreductive Surgery and HIPEC. Joel Baumgartner, MD, et. al. 8. Validation of the Peritoneal Surface Disease Severity Score in Patients with Sarcomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. George Salti, MD, et. al. 9. The Role of E2F1 in Well-Differentiated Papillary Mesothelioma of the Peritoneum (WDPMP). Gleneara Bates, MD, et. al. 10. Neutrophil-to-lymphocyte Ratio as a Predictor of Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Yttrium-90 Radioembolization. Daniel Sukato, MD, et. al. 11. Central Sarcopenia Does not Predict Occurrence of Clinically Dominant Acute Complication after Cytoreductive Abdominal Surgery in a Community Cancer Center. Shawna Grimm, MD, et. al. 12. Preoperative Ureteral Stenting for Patients Undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy. Carlos HF Chan, MD, et. al. 13. Current Trends in the Management of Malignant Peritoneal Mesothelioma. John Miura, MD, et. al. 14. Optimizing the Role of the Advanced Practice Provider in a HIPEC program. Deborah Schneider, et. al. 15. Development of a Cytoreductive Surgery and HIPEC Program: The Montefiore Einstein Experience. Oscar Serrano, MD, et. al. 16. Cytoreductive Surgery and HIPEC for Appendiceal Neoplasm: Delay to Treatment without Significant Consequence? Julie Alosi, MD, et. al. ~ 10 ~ ~ 11 ~
  • 7. 17. Cytoreductive Surgery and HIPEC for Malignant Peritoneal Mesothelioma: A Systematic Review. Joseph Helm, MD, et. al. 18. Role of Laparoscopy in Patients with Peritoneal Metastases Considered for Cytoreductive Surgery and HIPEC. Thejus Jayakrishnan, MD, et. al. 19. Role of Falciform Ligament and Ligamentum Teres Hepatis Resection in HIPEC. Thejus Jayakrishnan, MD, et. al. 20. Surgical Treatment for Mucinous Appendiceal Patients — The Role of Ostomies in Cytoreductive Surgery. Melanie Ongchin, MD, et. al. 21. Elevation of Alkaline Phosphatase Prior to Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors Predicts a Worse Outcome. Jill Onesti, MD, et. al. 22. Outcomes of Cytoreductive Surgery and HIPEC in Patients with High Grade-High Volume Disseminated Mucinous Appendiceal Neoplasms. Patricio Polanco, MD, et. al. 23. Outcomes of HIPEC Therapy at Low Volume Center. David Lee, MD, et. al. 24. Perioperative Clinical Factors May Predict Ineffectiveness of a Sole Epidural Based Pain Management Regimen for Patients Undergoing Cytoreductive Surgery with HIPEC. Jose Soliz, MD, et. al. 25. Peritoneal Mesothelioma in Mexico? Edgar Guillermo Flores-Ayala, MD, et. al. 26. Peritoneal Carcinomatosis from Lung Cancer: Is Debulking Surgery a Suitable Option in Selected Patients. Simone Sibio, MD, et. al. Norman Carr, MD Faculty of Medicine, University Hospital of Southampton Southampton, UK Course Co-Directors H. Richard Alexander, MD Professor of Surgery University of Maryland School of Medicine Baltimore, MD David L. Bartlett, MD Professor of Surgery University of Pittsburgh School of Medicine Robert P. Edwards, MD Professor, Obstetrics, Gynecology and Reproductive Sciences University of Pittsburgh School of Medicine T. Clark Gamblin, MD, MS Stuart D. Wilson Chair in Surgical Oncology Chief, Division of Surgical Oncology Associate Professor of Surgery Medical College of Wisconsin Milwaukee, WI 27. Sentinel Node Biopsy Under Local Anesthesia: The European Institute of Oncology Experience. Alessandro Testori, MD, et. al. Invited Faculty 28. Another Unusual Application of Cytoreductive Surgery and Hyperthermic Perioperative Chemotherapy to Definitely Treat a Rare Disease. Paul Sugarbaker, MD, et. al. Steven Ahrendt, MD Associate Professor of Surgery University of Pittsburgh School of Medicine 29. Prognostic Significance of Clinicopathological Parameters in Diffuse Malignant Peritoneal Mesothelioma. Sandy Liu, MD, et. al. Charlotte Ariyan, MD Associate Professor of Surgery Memorial Sloan-Kettering Cancer Center New York, NY 30. Immunotherapeutic Intra-arterial Adoptive Transfer In a Murine Model. Asher Blum, MD, et. al. 31. A Systematic Review and Meta-Analyses of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Lucas Boehm, MD, et. al. 32. Modified Vesicular Stomatitis Virus as Treatment of Peritoneal Surface Dissemination of Colorectal Cancer. Michelle L. Bryan, MD, et. al. 33. Concomitant Plural and Peritoneal Malignant Mesotheliomas: A single Institution Experience of 10 Cases. Jennifer Collins, MD, et. al. 34. Failure to Rescue in the Surgical Oncology Population. Katherine Kiolbasa, MD, et. al. 35. Survival, Morbidity and Peritoneal Carcinomatosis Index. Horacio Lopez-Basave, MD, et. al. ~ 12 ~ Division of Medicine and Oncology University of Pittsburgh School of Medicine C. Komen Brown, MD Cancer Treatment Centers of America Zion, IL James C. Cusack, MD Associate Professor of Surgery Harvard Medical School Massachusetts General Hospital Boston, MA Marcello Deraco, MD Surgical Oncologist Fondazione IRCCS Instituto Nazionale dei Tumori Milano, Italy Jesus Esquivel, MD Medical Director, International Oncology Initiatives Cancer Treatment Centers of America Philadelphia, PA Jason Foster, MD Assistant Professor of Surgery University of Nebraska Omaha, NE Martin Goodman, MD Assistant Professor of Surgery Tufts Medical Center Boston, MA Nathan Bahary, MD, PhD Associate Professor of Medicine Joel Baumgartner, MD University of California San Diego La Jolla, CA Haroon Choudry, MD Assistant Professor of Surgery University of Pittsburgh School of Medicine C. William Helm, MB.BChir Consultant Gynaecological Oncologist, Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital,  United Kingdom Marilyn Huang, MD Assistant Professor University of Pittsburgh School of Medicine ~ 13 ~
  • 8. Fabian Johnston, MD Assistant Professor of Surgery Medical College of Wisconsin Milwaukee, WI William Rilling, MD Associate Professor of Surgery Medical College of Wisconsin Milwaukee, WI John M. Kane III, MD Associate Professor of Oncology Roswell Park Cancer Institute Associate Professor of Surgery University at Buffalo Buffalo, NY Richard Royal, MD Associate Professor MD Anderson Cancer Center Houston, TX John H. Stewart, MD Associate Professor of Surgery Wake Forest University Winston-Salem, NC Timothy Kennedy, MD Assistant Professor of Surgery Montefiore Medical Center New York, NY Paul H. Sugarbaker, MD Director, Program in Peritoneal Surface Malignancy Washington Hospital Centre Washington, DC Daniel Labow, MD Associate Professor Mt. Sinai School of Medicine New York, NY Kiran Turaga, MD Assistant Professor of Surgery Medical College of Wisconsin Milwaukee, WI Laura Lambert, MD University of Massachusetts Memorial Medical Center Worcester, MA Douglas S. Tyler, MD Professor of Surgery Duke University Durham, NC Brian Loggie, MD Associate Professor of Surgery University of Nebraska Omaha, NE Herbert J. Zeh III, MD Associate Professor of Surgery University of Pittsburgh School of Medicine Garrett Nash, MD Associate Professor of Surgery Memorial Sloan Kettering Cancer Center New York, NY Amer Zureikat, MD Assistant Professor of Surgery University of Pittsburgh School of Medicine Steven J. O’Day, MD Beverly Hills Cancer Center Department of Medical Oncology Los Angeles, CA James Pingpank Jr., MD Associate Professor of Surgery University of Pittsburgh School of Medicine Faculty for this activity has been required to disclose all relationships with any proprietary entity producing health care goods or services. Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise. ~ 14 ~ Abstract/Poster Presenters Julie Alosi, MD Roswell Park Cancer Institute Buffalo, NY Fernando Arias, MD Hospital Universitario Fundacion Santa Fe de Bogota Bogota, Colombia Thomas Bachleitner-Hoffman, MD Medical University of Vienna Vienna, Austria Dario Baratti, MD Milan Tumor Institute Milan, Italy Edmund Bartlett, MD Hospital of the University of Pennsylvania Philadelphia, PA Gleneara Bates, MD Columbia University Medical Center New York, NY Lana Bijelic, MD Washington Hospital Center Washington, DC Asher Blum, MD Roswell Park Cancer Institute Buffalo, NY Lucas Boehm, MD Medical College of Wisconsin Milwaukee, WI Michelle L. Bryan, MD Wake Forest Baptist Health Winston-Salem, NC Carlos HF Chan, MD Massachusetts General Hospital Boston, MA Jennifer Collins, MD University of Maryland Medical Center Baltimore, MD Daniel Cucher, MD University of Arizona Tucson, AZ Jason Denbo, MD University of Tennessee Health Sciences Center Memphis, TN Andrea Doud, MD Wake Forest Baptist Health Winston-Salem, NC Stephanie Downs-Canner, MD UPMC Shadyside Pittsburgh, PA Edgar Guillermo Flores-Ayala, MD Hospital Regional de Alta Especilidad de Oaxaca Oaxaca, Oaxaca, Mexico Jan Franko, MD Mercy Medical Center Des Moines, IA Bernardo Franssen, MD Mount Sinai School of Medicine New York, NY Evan Glazer, MD The University of Arizona Tucson, AZ Shawna Grimm, MD Mercy Medical Center Des Moines, IA Andrea Hayes-Jordan, MD Assistant Professor of Pediatric Surgery University of Houston MD Anderson Cancer Center Houston, TX ~ 15 ~
  • 9. Joseph Helm, MD Medical College of Wisconsin Milwaukee, WI Shigeki Kusamura, MD Istituto Nazionale Tumori di Milano Milano, Italy John Miura, MD Medical College of Wisconsin Milwaukee, WI Lawrence Shirley, MD Ohio State University Columbus, OH Chukwuemeka Ihemelandu, MD Medstar Washington Hospital Center Washington, DC Mei Li Kwong, MD National Cancer Institute, NIH Simone Sibio, MD Bethesda, MD Maria Nunez, MD Mercy Medical Center Baltimore, MD Thejus Jayakrishnan, MD Medical College of Wisconsin Milwaukee, WI David Lee, MD St. Luke’s Roosevelt Hospital New York, NY Jill Onesti, MD The Ohio State University Columbus, OH Jose Soliz, MD MD Anderson Cancer Center Houston, TX David Jeffcoach, MD University of Tennessee Medical Center Knoxville, TN Faina Linkov, MD University of Pittsburgh Pittsburgh, PA Melanie Ongchin, MD University of Pittsburgh Pittsburgh, PA Charles Staley, MD Emory University Atlanta, GA Betty Jiang, MD Duke University Medical Center Durham, NC Sandy Liu, MD University of Maryland Medical Center Baltimore, MD Patricio Polanco, MD University of Pittsburgh Pittsburgh, PA Daniel Sukato, MD University of Pittsburgh Pittsburgh, PA Kaitlyn Kelly, MD University of California San Diego La Jolla, CA Horacio Lopez-Basave, MD Instituto Nacionale de Cancerologia de Mexico Distrito Federal, Mexico Nelson Royall, MD MD Anderson Cancer Center Orlando Orlando, FL Parissa Tabrizian, MD Mount Sinai Medical Center New York, NY George Salti, MD The University of Illinois at Chicago Chicago, IL Alessandro Testori, MD European Institute of Oncology Milan, IT Paolo Sammartino, MD University of Rome Rome, Italy Samer Tohme, MD University of Pittsburgh Pittsburgh, PA Neil Saunders, MD The Ohio State University Columbus, OH Patrick Wagner, MD Winchester Medical Center Winchester, VA Deborah Schneider Medical College of Wisconsin Milwaukee, WI Harold Wanebo, MD Landmark Medical Center Woonsocket, RI Oscar Serrano, MD Montefiore-Einstein Center for Cancer Care Bronx, NY Yutaka Yonemura, MD Haruki-Moto-Machi Kishiwada, Osaka, Japan Oliver Shihab, MD North Hampshire Hospital Anthony Zacharias, MD Medical College of Wisconsin Milwaukee, WI Minhyung Kim, MD Roswell Park Cancer Institute Buffalo, NY Teresa Kim, MD Massachusetts General Hospital Boston, MA Katherine Kiolbasa, MD Froedtert Hospital Milwaukee, WI Joji Kitayama, MD University of Tokyo Tokyo, Japan Russell Low, MD Sharp Memorial Hospital San Diego, CA Robert Martin, MD University of Louisville Louisville, KY J. Andrea McCart, MD Toronto General Research Institute Toronto, Ontario, Canada Yarrow McConnell, MD University of Calgary Calgary, Alberta, Canada Sarah McPartland, MD Tufts Medical Center Boston, MA Basingstoke, UK ~ 16 ~ University Sapienza of Rome Rome, Italy ~ 17 ~
  • 10. Registration Information Meeting Location Online Registration is accepted until February 14, 2014. After this date, you are only able to register for the conference on site. The conference will be held at the Sheraton Steamboat Springs, 2220 Village Inn Court, PO Box 774808. Conference reservations are at the sole responsibility of the attendees who may contact the hotel. Registering online is the quickest and easiest way to reserve your space at CCEHS conferences. Visit our online registration site at https://ccehs.upmc.com. Scroll down to the Ninth International Symposium on Regional Cancer Therapies section on the web page.    •  Click the registration button and enter all of the requested information.    •  After registering, an electronic confirmation will be sent to the email address you provided when you registered. Registration is not complete until you receive the confirmation email for your preregistration. If you do not receive this letter within 5-7 days of registration, please contact Maureen Hewko at (412) 623-5993. You must bring this confirmation with you to the conference. Registration Cancellation All cancellations must be in writing and sent to us via US mail, email or fax. Tuition cancellations postmarked or date stamped before January 15, 2014 will be completely refunded. After January 15, 2014, a $35 administrative fee will be assessed. No refunds will be made after February 1, 2014. Conference contact for cancellation requests: Maureen Hewko, MBA UPMC Cancer Pavilion 413, 5150 Centre Avenue Pittsburgh, PA 15232 Email: hewkom@upmc.edu  •  Telephone: (412) 623-5993 Fax: (412) 692-2520 Registration Fees $300  Physicians and researchers $200  Nurses and other health care professionals Registration fee includes: •  Continuing education credit •  Registration and course materials •  Continental breakfast, refreshments and a light dinner ~ 18 ~ If registering for a room at the hotel online, please go to https:/ /www.starwoodmeeting. com/StarGroupsWeb/booking/reservation?id=1308271577&key=5F82A If you wish to make your reservation by phone, please call John at 970-871-6550 and ask for the UPP room block. Accommodations Nightly Guest Room Rates: $289 per night Note: Resorts room rates are subject to additional taxes and resort fees as applicable. Transportation For up-to-date transportation information, go to the Koch Center Website: http://www.regionaltherapies.com For additional information, contact: Maureen Hewko, MBA Telephone: (412) 623-5993 Fax: (412) 692-2520 Email: hewkom@upmc.edu Koch Center Website: http://www.regionaltherapies.com Visit the Center for Continuing Education in the Health Sciences Web Site Our Internet address is: https://ccehs.upmc.com The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs. ~ 19 ~